Financial
Latest full-year results from official filings.
FY2026 revenue $254.25bn (+14.0%); operating margin 1.0%; net income $1.71bn.
Cash $4.86bn; debt $8.89bn.
- Official results release · Cardinal Health · 30 Jun 2026
Cardinal Health: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Cardinal Health found in HSH's search of the last 24 months; lawsuit settlements found (kickbacks, opioid oversight) date from 2022. Aug 2025: Cardinal agreed to buy US urology group Solaris Health for $1.9bn.
- Cardinal Health reports flat 4Q revenue, higher profit and a $1.9B acquisition · Modern Distribution Management · 1 Aug 2025
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Cardinal Health found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
Jul 2026: Cardinal Health began a Class 2 FDA recall of 616 Presource surgical kits (US and Canada) containing third-party neurological sponges recalled for variable endotoxin levels.
- FDA recall Z-2949-2026: Cardinal Health Presource kits · US FDA · 13 Aug 2026
Contract performance
Contract delivery, go-lives, terminations and disputes.
Jun 2025: a large pharmaceutical distribution contract with Optum (UnitedHealth Group), reported as about 15% of revenue, expired, leaving Cardinal's reported sales roughly flat for the quarter.
- Cardinal Health reports flat 4Q revenue, higher profit and a $1.9B acquisition · Modern Distribution Management · 1 Aug 2025